Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 3/20 | 0.81 |
| ▸ | NPC1 | O15118 | 5/20 | 0.66 |
| ▸ | RAB9A | P51151 | 4/20 | 0.66 |
| ▸ | CASP3 | P42574 | 1/20 | 0.65 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.65 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.65 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.65 |
| ▸ | MITF | O75030 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20836388 | 0.99 | NR4A2 (0.80) | NR4A2NPC1RAB9ACASP3SENP8 | |
| SCHEMBL11615525 | 0.90 | NR4A2 (0.83) | NR4A2NPC1RAB9ACASP3SENP8 | |
| SCHEMBL2488636 | 0.90 | NR4A2 (1.00) | NR4A2NPC1RAB9ACASP3SENP8 | |
| SCHEMBL11409473 | 0.90 | NR4A2 (1.00) | NR4A2NPC1RAB9ACASP3SENP8 | |
| SCHEMBL6069179 | 0.86 | NR4A2 (1.00) | NR4A2NPC1RAB9ACASP3SENP8 | |
| SCHEMBL2482452 | 0.86 | NR4A2 (1.00) | NR4A2NPC1RAB9ACASP3SENP8 | |
| SCHEMBL11613581 | 0.86 | NR4A2 (0.77) | NR4A2NPC1RAB9ACASP3SENP8 | |
| SCHEMBL11617795 | 0.84 | NR4A2 (0.79) | NR4A2NPC1RAB9ACASP3SENP8 | |
| SCHEMBL17965446 | 0.83 | NPC1 (0.89) | NR4A2NPC1RAB9ACASP3SENP8 | |
| SCHEMBL6068962 | 0.81 | NR4A2 (0.80) | NR4A2NPC1RAB9ACASP3SENP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4650001-A2 | FUSED HETEROCYCLIC DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTOR | Neurosterix Pharma Sàrl (CH) | 2025-11-19 | — | — | EP | disclosed |
| EP-4337664-B1 | FUSED HETEROCYCLIC DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTOR | ADDEX PHARMACEUTICALS SA (CH) | 2025-10-01 | — | — | EP | disclosed |
| EP-4619101-A1 | NOVEL PYRROLO[1,2-d][1,2,4]TRIAZINONE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTORS | Neurosterix Pharma Sàrl (CH) | 2025-09-24 | — | — | EP | disclosed |
| EP-4619100-A1 | NOVEL BICYCLIC[1,2,4]TRIAZOLONE DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTORS | Neurosterix Pharma Sàrl (CH) | 2025-09-24 | — | — | EP | disclosed |
| US-20240327375-A1 | SUBSTITUTED HETEROBICYCLIC DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTOR | ADDEX PHARMA S.A. (CH) | 2024-10-03 | — | — | US | disclosed |
| US-20240262833-A1 | FUSED HETEROCYCLIC DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTOR | ADDEX PHARMA S.A. (CH) | 2024-08-08 | — | — | US | disclosed |
| EP-4337664-A1 | FUSED HETEROCYCLIC DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTOR | Addex Pharma S.A (CH) | 2024-03-20 | — | — | EP | disclosed |
| EP-4337643-A1 | SUBSTITUTED HETEROBICYCLIC DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTOR | Addex Pharma S.A (CH) | 2024-03-20 | — | — | EP | disclosed |
| WO-2022238580-A1 | FUSED HETEROCYCLIC DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTOR | ADDEX PHARMA S.A. (CH) | 2022-11-17 | — | — | WO | disclosed |
| CN-111148744-A | Novel heterocyclic compounds as MGLUR7 modulators | 布拉格玛治疗公司 | 2020-05-12 | — | — | CN | disclosed |
| EP-3039126-B1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADSTONE (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20160250260-A1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-01 | — | — | US | disclosed |
| EP-3039126-A2 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2016-07-06 | — | — | EP | disclosed |
| WO-2015041809-A2 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-03-26 | — | — | WO | disclosed |
| US-20100197800-A1 | Treatment and/or Prevention of Presbycusis by Modulation of Metabotropic Glutamate Receptor 7 | UNIVERSITY OF ANTWERP (BE) | 2010-08-05 | — | — | US | disclosed |
| US-20100197800-A1 | Treatment and/or Prevention of Presbycusis by Modulation of Metabotropic Glutamate Receptor 7 | UNIVERSITY OF ANTWERP (BE) | 2010-08-05 | — | — | US | disclosed |
| US-20100197800-A1 | Treatment and/or Prevention of Presbycusis by Modulation of Metabotropic Glutamate Receptor 7 | UNIVERSITY OF ANTWERP (BE) | 2010-08-05 | — | — | US | disclosed |
| EP-2150244-A1 | TREATMENT AND/OR PREVENTION OF PRESBYCUSIS BY MODULATION OF METABOTROPIC GLUTAMATE RECEPTOR 7 | HOUSE EAR INSTITUTE (US) | 2010-02-10 | — | — | EP | disclosed |
| WO-2008131439-A1 | TREATMENT AND/OR PREVENTION OF PRESBYCUSIS BY MODULATION OF METABOTROPIC GLUTAMATE RECEPTOR 7 | HOUSE EAR INSTITUTE (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008131439-A1 | TREATMENT AND/OR PREVENTION OF PRESBYCUSIS BY MODULATION OF METABOTROPIC GLUTAMATE RECEPTOR 7 | HOUSE EAR INSTITUTE (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262833-A1 | FUSED HETEROCYCLIC DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTOR | GRM7, GRM1, GRM2 | NR4A2 352/4885NPC1 1804/4885RAB9A 1191/4885 |
| US-20100197800-A1 | Treatment and/or Prevention of Presbycusis by Modulation of Metabotropic Glutamate Receptor 7 | GRM7, GRM3, GRM5 | NR4A2 901/4885NPC1 824/4885RAB9A 2982/4885 |
| US-20240327375-A1 | SUBSTITUTED HETEROBICYCLIC DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTOR | GRM7, GRM2, GRM1 | NR4A2 339/4885NPC1 2174/4885RAB9A 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.